Matthew S. Davids, MD, MMSc
Single-agent venetoclax (Venclexta) led to durable responses in patients with relapsed/refractory mantle cell lymphoma (MCL) with a low rate of late-onset toxicities, according to long-term follow-up of a dose-escalation phase I trial presented at the 2018 ASH Annual Meeting.1
Of the 11 deaths, 3 occurred ≤30 days after discontinuing venetoclax because of disease progression and 8 occurred ≥30 days after discontinuation with 6 related to progression, 1 to pneumonia, and 1 to pulmonary hemorrhage. Further studies in MCL are currently investigating potential biomarkers for durable response to venetoclax combination regimens, including the phase III SYMPATICO randomized study comparing venetoclax plus ibrutinib versus ibrutinib alone.
- Davids MS, Roberts AW, Wierda WG, et al. Long-term follow-up of patients with mantle cell lymphoma treated with venetoclax monotherapy. Presented at: 2018 ASH Annual Meeting; Dec. 1-4, 2018; San Diego, CA. Abstract 2883.
- Davids MS, Roberts AW, Seymour JF, et al. Phase 1 first-in-human study of eventioclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35:826-833. doi: 10.1200/JCO.2016.70.4320.
... to read the full story